Risk of SARS-Cov-2 Infection Among Proton Pump Inhibitors Users:

Abstract

Public health is affected seriously by COVID-19. Its mortality rate varies within different nations and identification of its risk factors is in progress. Here, we systematically reviewed articles that have evaluated the association between proton pump inhibitors (PPIs) intake and SARS-CoV-2 infection.

PubMed, Google Scholar, Scopus, and Cochrane databases from their inception till 2^nd December 2020 were systematically searched to obtain any possible article for inclusion.

Results of this research reveal that After screening and removing unrelated or duplicate articles by the title and abstract by two independent reviewers, 6 articles were included. Results revealed a direct and dose-dependent relationship among PPIs intake and possibility of infection with SARS-CoV-2, the severity of the clinical manifestations of the COVID-19, and expression of SARS-CoV-2 receptors in the kidney and liver tissues.

In Conclusion, PPIs increase the risk of the infection with SARS-CoV-2 and cause severe clinical outcomes in the COVID-19 patient. They should be used when a clear indication is present at the lowest effective dose.